Compare Immunovant Inc. Common Stock (IMVT) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs iShares Silver Trust — how do they compare? Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B), while iShares Silver Trust trades at $54.4 (market cap $29.02B). The key difference: iShares Silver Trust is far larger — about 4.6× Immunovant Inc. Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and iShares Silver Trust for 89 Days on average.
| IMVT | SLV | |
|---|---|---|
Market Cap | $6.25B | $29.02B |
Volume | 1,755,411 | 16,510,334 |
Sector | Health | — |
52-Week High | $44.96 | $105.57 |
52-Week Low | $17.03 | $42.40 |
Typical Hold Time | 0 Days | 89 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLV (iShares Silver Trust) is trading at $53.82, down 2.94% with a bearish technical outlook. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Technical indicators show strong bearish momentum with 13 sell signals from moving averages, though RSI suggests potential oversold conditions. Recent news highlights silver's volatility amid Fed policy uncertainty and Treasury yield fluctuations.
Outlook remains cautious as silver faces pressure from rising rates and dollar strength. The ETF's structure provides pure silver exposure but carries metal price volatility risks. Near-term direction depends on Fed policy clarity and industrial demand trends, with technical support at $53-54 levels offering potential entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
